Related Experiment Video
Updated: Jul 16, 2026
04:22
Biomarker Identification for Gender Specificity of Alzheimer's Disease Based on the Glial Transcriptome Profiles
Published on: May 20, 2024
Somatotype in Alzheimer's disease
Roberto Buffa1, Marco Lodde, Giovanni Floris
1Dipartimento di Biologia sperimentale, Sezione di Scienze antropologiche, Università di Cagliari, Cagliari, Italy.
Gerontology
|March 10, 2007
Summary
Alzheimer
Area of Science:
- Gerontology
- Neurology
- Anthropometry
Background:
- Alzheimer's disease (AD) presents with variations in anthropometry and body composition.
- Somatotyping offers a non-invasive method for assessing body types.
Purpose of the Study:
- To characterize the somatotype of individuals with mild-to-moderate Alzheimer's disease.
- To compare the somatotypes of Alzheimer's patients with a healthy control group.
Main Methods:
- The Heath-Carter somatotype method was employed.
- A sample of 55 Alzheimer's patients (mild-moderate stage) was assessed.
- A control group of 280 healthy individuals was included for comparison.
Main Results:
- Alzheimer's patients exhibited significantly lower mesomorphy and higher ectomorphy compared to controls, particularly in women.
- Mean somatotype for male AD patients: 6.1-5.5-0.8; female AD patients: 7.0-5.3-0.7.
- Mean somatotype for male controls: 6.1-6.3-0.6; female controls: 7.7-6.3-0.4.
Conclusions:
- Alzheimer's disease patients display distinct somatometric characteristics.
- Somatotyping is a valuable technique for studying and monitoring physical changes in Alzheimer's patients.
Related Concept Videos
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:11Alterations in Muscle Tone lll
Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...